MLTXMoonLake Immunotherapeutics

1. Sep 30, 2026On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the treatment of moderate-to-severe hidradenitis suppurativa in adults and pediatric …Other event · Form 8-K
2. Aug 10, 2026MoonLake Announces Positive Topline Results.Earnings release · press release
3. Jul 15, 2026On July 10, 2026, the underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of MoonLake Immunotherapeutics (the “Company”) and, in lieu of Ordinary Shares to certain investors that so choose, pre-funded warrants to purchase Ordinary …Other event · Form 8-K
4. Jun 25, 2026On June 23, 2026, MoonLake Immunotherapeutics (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Leerink Partners LLC, as the representative of the underwriters named therein (the “Underwriters”), to issue and sell, in a public offering (the “Offering”), 9,000,000 Class A ordinary …Material agreement entered · Form 8-K
5. Jun 22, 2026Results from the Phase 3 VELA clinical trials at Week 52 Week 52 data for SLK showed consistent and further improvement in all clinical scores, compared to Week 16 data.Regulation FD disclosure · Form 8-K
6. Jun 9, 2026At the Annual Meeting, the Company’s shareholders approved an amendment and restatement of the Company’s 2022 Equity Incentive Plan (as so amended, the “Plan”) to increase the number of Class A Ordinary Shares available for stock-based awards by 5,000,000 shares, remove liberal share recycling provisions, incorporate …Director or officer change · Form 8-K
7. Jun 1, 2026On May 22, 2026, MoonLake Immunotherapeutics (the “Company”) entered into a Master Commercial Supply Agreement (the “Vetter MCSA”) with Vetter Pharma International GmbH (“Vetter”)Material agreement entered · Form 8-K
8. Feb 23, 2026On February 20, 2026 (the “Amendment Closing Date”), MoonLake Immunotherapeutics (the “Company”), as a guarantor, entered into a first amendment to loan and security agreement (the loan and security agreement, as so amended, the “Amended Loan and Security Agreement”) with its subsidiary, MoonLake Immunotherapeutics …Material agreement entered · Form 8-K
9. Jan 8, 2026On January 8, 2026, MoonLake Immunotherapeutics (the “Company”) issued a press release providing an update following the positive feedback received from the U.S. Food and Drug Administration regarding the clinical evidence strategy for Sonelokimab (“SLK”) in Hidradenitis Suppurativa, based on the Type B meeting …Other event · Form 8-K
10. Nov 5, 2025On November 5, 2025, MoonLake Immunotherapeutics (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Leerink Partners LLC as the underwriter named therein (the “Underwriter”), to issue and sell 7,142,857 Class A ordinary shares, par value $0.0001 per share (the “Shares”), at an …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.